HaploX
PrivateLast Round
Series D
Jul 26, 2022
Est. Valuation
$445.77M
Total Funding Raised
$110.95M
Company Overview
HaploX is a biotechnology company that provides genetic testing solutions, specializing in liquid biopsy, gene sequencing, bioinformatics, and big data analytics for cancer management and hereditary disease screening.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Medical Devices, Biotech Equipment
Business Model
B2B
Customer Profile
Services & Consulting, Hardware + Subscription
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
HaploX Comparables
Compare HaploX with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Beijing Geneplus Technology | 93% | |
| 求臻医学 | 89% | |
| New Genetron Holding Limited | 86% |
For institutional investors. Book with your work email.
HaploX Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Jul 26, 2022 | ||||
| Series C | Jul 1, 2021 | ||||
| Series B Extension | Apr 1, 2020 | ||||
| Series B | Jun 28, 2018 | ||||
| Series A Extension | Dec 1, 2017 | ||||
Series A | Apr 30, 2016 |
For institutional investors. Book with your work email.
HaploX Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Kexin Capital | Series A Extension |
| Youxuan Capital | Series A Extension |
| Grains Valley Venture Capital | Angel |
| Efung Capital | Series B |
| SB China Capital | Series A Extension, Series D, Series A |
| Shenzhen Capital Group | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- May 17, 2024
Grew 16% QoQ, from 19 to 22 employees.
- Jul 26, 2022
$22M round led by SB China Capital
For institutional investors. Book with your work email.
HaploX Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about HaploX's valuation, stock price, and market status.
Is HaploX a public or private company?
HaploX is a private company.
What is the current stock price of HaploX?
HaploX is a private company, so its shares have no public market price. Caplight tracks HaploX's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is HaploX worth (valuation)?
HaploX's valuation is estimated at $445.8M based on funding round data.
Can I buy HaploX stock?
HaploX shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was HaploX's last funding round?
HaploX's most recent funding round was Series D on July 26, 2022.
Who are the main investors in HaploX?
Key investors in HaploX include SB China Capital, Shenzhen Capital Group.
Will HaploX IPO soon?
No public IPO plans have been announced for HaploX.
How can I track HaploX secondary market activity?
Caplight tracks bids, offers, and trades in HaploX's shares on secondary markets.